Board summary
Key figures
21,036
Registered population
61.5% aged 18–64
17.1%
Aged 65+
ICB 18.8% · England 17.9%
14.1%
Ethnic minority (non-White)
6.4% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 0.8% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
2,727
Hypertension register
+1.22% in 3 yrs · England +5.60%
197
SMI register
17.4% of Elmbridge's
231
COPD register
Reviews +13.36% in 3 yrs
Forecast to 2030
2,863
Hypertension patients, 2030
+136 on today
62.4%
QRISK ≥20% on statins, 2030
+1.23pp over 3 yrs
3.7%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Cardiovascular and diabetes control slipped over three years.
Over 2023 to 2025, non-frail diabetes HbA1c control changed -4.2% (England +4.4%), under-80 BP control -3.5% (England +3.2%), with QRISK >= 20% lipid therapy.
Age-five booster drop-off and wide practice variation.
In Q1 2025/26, age-5 MMR coverage dropped 10.2 pp from dose 1 (92.6%) to dose 2 (82.4%), 4-in-1 reached 76.5%, and QOF vaccination spanned.
Strong COPD review and psychosis recording gains.
COPD annual reviews reached 84.4% (+13.4% over 2023 to 2025 vs England +2.8%), and psychosis alcohol recording rose +21.3 pp to 88.7% (England 81.8%).
Population, age and ethnicity
A list of 21,036 patients has a younger profile alongside 215 care beds
Walton Practices Confederation PCN registers 21,036 patients. Children aged 0–17 comprise 21.5% (4,515 patients), compared with 21.7% in Elmbridge, 20.4% in NHS Surrey Heartlands ICB and 19.6% in England. Those aged 65+ represent 17.1% (3,588 patients), below Elmbridge (17.9%), the ICB (18.8%) and England (17.9%), while 61.5% (12,933) are aged 18–64. Ethnicity data reflects Census usual residents in associated areas rather than registered patients: 85.9% are White (Elmbridge 86.1%, ICB 85.3%, England 81.1%) and 14.1% belong to ethnic minorities, including 6.4% Asian residents (Elmbridge 6.5%, ICB 7.7%, England 9.6%).
Age profile
65+: ICB 18.8%, England 17.9%
Ethnicity
Older people · falls rows are Elmbridge local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Elmbridge LA) | 2,003 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 76.0% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.7% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Elmbridge LA) | 895 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Elmbridge LA) | 10.4 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Average IMD decile is 7.7 with 0.0% of registered patients in Core20 areas
Walton Practices Confederation PCN records 0.0% of its 21,036 registered patients in Core20, matching Elmbridge (0.0%) and below NHS Surrey Heartlands Integrated Care Board (0.8%) and England (21.0%). Average IMD decile is 7.7 (Elmbridge 8.6, ICB 7.9, England 5.5). Core20 share is 0.0% across all four practices (0 estimated patients); captured practice IMD deciles are 7.7 at The Yellow Practice and 8.1 at The Red Practice Walton. With zero Core20 area deprivation, local inequality work may achieve greater reach by targeting vulnerable clinical and inclusion cohorts.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
197
SMI register
0.89% recorded prevalence
88
Learning disability register
0.40% recorded prevalence
5
Care homes, 215 beds
In the PCN catchment
7.4%
Provide unpaid care
Elmbridge, Census 2021
Recorded inclusion registers include 197 patients with severe mental illness (0.9% vs Elmbridge 0.7%, ICB 0.8%, England 1.0%) and 88 with learning disabilities (0.4% vs Elmbridge 0.3%, ICB 0.5%, England 0.6%). Catchment care capacity spans 215 beds across five homes.
Severe mental illness: physical health checks
Severe mental illness blood pressure check completion reached 78.2% across 197 patients, trailing England (83.4%) despite a +14.5 pp rise over 2023 to 2025 (England +4.4 pp). Ashley Medical Practice recorded 53.3%.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
2,727
Hypertension register
+1.22%
Register growth, 3 yrs
Elmbridge +5.83% · England +5.60%
−2.60pp
BP control, under 80
≤140/90 · −1.97pp aged 80+
+136
More patients by 2030
Forecast 2,863 (12.63%)
Hypertension case-finding and control
Hypertension register prevalence is 12.3% (2,727 patients), below Elmbridge (12.6%), NHS Surrey Heartlands Integrated Care Board (14.3%) and England (15.2%). Blood pressure treated to target is 74.5% (England 70.3%) and under-80s control is 72.3% (England 67.8%). However, over 2023 to 2025, patients treated to target fell 2.9% (England +3.6%) and under-80s control fell 3.5% (England +3.2%).
Lipids and statins
Lipid-lowering therapy uptake for QRISK ≥ 20% patients is 59.9%, trailing England (63.6%) while exceeding Elmbridge (55.9%). Over 2023 to 2025, uptake rose +2.1%, lagging England (+6.2%) and NHS Surrey Heartlands Integrated Care Board (+6.1%).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 25,706 | £2.10 | £2.24 | £1.86 | £53,983 |
| Cardiovascular (all), 2025 | 38,953 | £4.83 | £4.74 | £3.33 | £188,143 |
For lipid-regulating drugs in 2026, the PCN prescribed 25,706 items with an annual spend of £53,983 at £2.10 per item, compared to England (£1.86), Elmbridge (£2.25) and NHS Surrey Heartlands Integrated Care Board (£2.24). Across these items, the PCN spends £6,169 more than at England's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+1.98%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+4.57%
Asthma prevalence, PCN 3-yr % change
COPD annual reviews reached 84.4% across 231 patients, exceeding England (76.4%) following a +13.4% change over 2023 to 2025 (England +2.8%). Asthma annual reviews reached 69.1% (England 65.7%, Elmbridge 61.6%), leaving about 280 patients (277) without a recorded review on the 896-patient register. For patients aged 5–19, asthma management prescribing was 1,156 rate per 1,000, below England (1,488 rate) and above Elmbridge (732 rate).
Cancer register and children's immunisation
In Q1 2025/26, 24-month 6-in-1 coverage was 96.2%, exceeding the 95.0% target. At age 5, coverage was 82.4% for MMR dose 2 (below the 95.0% target by 12.6 pp) and 76.5% for the 4-in-1 booster (below the 95.0% target by 18.5 pp), with a 10.2 pp drop between MMR doses. Cancer prevalence is 3.3% (727 patients; England 3.8%).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
61.4%
Surrey Heartlands ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~650
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Surrey Heartlands ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 65.7% | 53.2% | 18% | 1,044 |
| Breast | 88.2% | 85.4% | 27% | 798 |
| Bowel | 48.1% | 47.0% | 18% | 626 |
| Lung | 33.2% | 33.8% | 17% | 497 |
| Skin cancer | 89.8% | 87.8% | 19% | 384 |
In 2022, across NHS Surrey Heartlands ICB (wider system data, not PCN level), 61.4% of staged cancers (2,955 of 4,810) were diagnosed at stage 1 or 2, above England (55.3%) but 13.6 pp below the 75.0% national ambition, with staging known for 67.7% (4,810 of 7,106). Reaching 75.0% requires about 650 additional early diagnoses across the ICB. At PCN level, cervical screening coverage in women aged 25–49 is 65.7% (England 66.8%, ICB 69.3%), with Ashley Medical Practice at 56.3%. PCN breast screening coverage is 68.5% (ICB 71.2%).
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), for wider trust performance (not PCN performance), Ashford and St Peter's Hospitals NHS Foundation Trust achieved 76.4% for the 62-day referral to treatment standard (standard 85.0%), exceeding NHS Surrey and Sussex Integrated Care Board (71.5%) and England (71.2%). Epsom and St Helier University Hospitals NHS Trust achieved 86.8% and Kingston and Richmond NHS Foundation Trust 75.3%. Ashford and St Peter's met the 28-day faster diagnosis standard at 85.5% (standard 75.0%). Trust diagnostic 6+ week waits were 57.9% for flexi sigmoidoscopy, 56.7% for gastroscopy and 49.6% for colonoscopy.
| Pathways within standard (%) | Ashford and St Peter's | Kingston and Richmond | Epsom and St Helier | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 85.53 | 80.07 | 89.70 | 79.29 | 79.32 |
| 31-day treatment (96%) | 94.21 | 98.77 | 99.16 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 76.38 | 75.32 | 86.82 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Ashford and St Peter's | Kingston and Richmond | Epsom and St Helier | England |
|---|---|---|---|---|
| MRI | 0.09 | 0.19 | 0.31 | 21.40 |
| CT | 9.27 | 0.00 | 1.06 | 9.92 |
| Echocardiography | 0.97 | 4.89 | 25.49 | 28.48 |
| Colonoscopy | 49.61 | 70.17 | 33.01 | 30.83 |
| Gastroscopy | 56.74 | 79.18 | 30.90 | 29.02 |
| All 15 DM01 tests | 23.12 | 31.56 | 6.83 | 23.14 |
| Community services activity | Surrey residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 109,530 | 309,615 |
| Referrals | 28,700 | 66,930 |
| Patients with a contact | 33,510 | 85,660 |
Community services (residents of Surrey), Jun 2026 (provisional). In Jun 2026 (provisional), at local authority level (not PCN performance), adults aged 65 and over accounted for 69.6% of all community service contacts among Elmbridge borough residents (76,215 of 109,530 contacts). This borough-level concentration highlights that community care contacts are heavily concentrated among older residents.
Practice variation and patient experience
Vaccination achievement spans 51.3 percentage points and phone access spans 33.0 percentage points
In 2025/26, QOF vaccination achievement spanned 51.3 percentage points, from 47.3% at Ashley Medical Practice to 98.6% at The Red Practice Walton. Clinical achievement was 100.0% at Ashley Medical Practice alongside a 21.4% personalised care adjustment rate; local administrative and recall audits would be required to test variation across practices.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Red Walton | 109 | 0.0 | 41.6% | 71.5% | 82.4% |
| Yellow | 101 | 0.0 | 47.4% | 51.2% | 75.3% |
| The White Practice | 89 | 0.0 | 74.6% | 69.3% | 73.1% |
| Ashley Medical | 87 | 0.0 | 49.9% | 63.8% | 58.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fifteen of 25 three-year trends lagged England despite mental health and respiratory gains
Across 2023 to 2025, 15 of 25 tracked measures trailed England. The widest three-year relative declines were in heart failure reviews, down 0.2% (England +8.7%), non-frail diabetes HbA1c control, down 4.2% (England +4.4%), and stroke prevalence, down 5.8% (England +2.3%). Under-80 blood pressure control also fell 3.5% (England +3.2%). Conversely, severe mental illness checks rose sharply: psychosis alcohol recording increased +21.3 pp (England +5.4 pp) and blood pressure checks rose +14.5 pp (England +4.4 pp), alongside COPD reviews rising +13.4% (England +2.8%). The PCN could prioritise arresting cardiovascular and diabetes delivery slippage.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Diabetes HbA1c control
Stroke register
BP control, under 80
Hypertension treated to target
Alcohol record (psychosis)
COPD reviews
BP check (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Elmbridge | Asset | PCN | Elmbridge |
|---|---|---|---|---|---|
| Care homes (catchment) | 5 (215 beds) | n/a | Schools (catchment) | 27 | n/a |
| Children's centres | 2 | 8 | Places of worship | 18 | 59 |
| Libraries | 2 | 6 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | n/a | 2 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 2 | 15 | Primary academies | 3 | 11 |
| Special schools | n/a | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Targeted SMI blood pressure recall
SMI register with a BP check in the last 12 months is 78.2% (current basis, with 197 patients on the SMI register, despite a +14.5 pp 3-year change from 2023 to 2025), compared with Elmbridge (81.7 percent, -3.5 percentage points), NHS Surrey Heartlands Integrated Care Board (83.5 percent, -5.3 percentage. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 2
Asthma annual review recall
Asthma review completion is 69.1% on the 896-patient register (England 65.7%, Elmbridge 61.6%), leaving 277 patients (about 280) without a recorded review. For discussion: practices could run a single-template recall for unreviewed asthma patients, pairing inhaler checks with flexible review slots. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Age-five pre-school booster recall
In Q1 2025/26 (cohort 68), age 5 coverage was 82.4% for MMR2 (below 95.0% by 12.6 pp) and 76.5% for 4-in-1 (below by 18.5 pp), dropping 10.2 pp from MMR1 (92.6%). Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Inclusion health cohort audit (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Severe mental illness outreach (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice access and triage review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Targeted SMI blood pressure recall (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN & Practice |
| Option 2 · Asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · Age-five pre-school booster recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
